Literature DB >> 24780703

Development, validation and application of an HPLC-MS/MS method for the determination of fentanyl and nor-fentanyl in human plasma and saliva.

Sudeep R Bista1, Michael Lobb2, Alison Haywood3, Janet Hardy2, Angela Tapuni2, Ross Norris4.   

Abstract

Monitoring fentanyl concentration in saliva and plasma may be useful in pharmacokinetic/pharmacodynamic studies. Salivettes(®) have been used widely for collecting saliva samples. However due to its lipophilicity, fentanyl adsorbs to the cotton dental bud (CDB) used in this device. Furthermore, due to dry mouth being a common adverse effect seen in patients treated with opioids, obtaining enough saliva for analysis is often a challenge. Hence, a simple simultaneous method to quantify fentanyl and its metabolite in both human plasma and saliva was developed and validated. A novel extraction method was also developed and validated to recover fentanyl in saliva directly from the CDB. This extraction method utilises acetonitrile to recover the fentanyl directly from the CDB rather than recovery by centrifugation, which is not always possible. Reverse phase chromatographic separation was performed on a Shimadzu LC 20A HPLC system using gradient elution. The electrospray ion source (ESI) was operated in positive ion mode using an Applied Biosystems API 3200 LC/MS/MS as detector. Deuterated fentanyl (D5) and nor-fentanyl (D5) were used as internal standards (IS). The retention times for fentanyl and nor-fentanyl were 3.70 min and 3.20 min respectively. The lower limit of quantitation (LLOQ) was determined to be 0.030 μg/L in plasma and 0.045 in saliva for fentanyl and nor-fentanyl. Acceptable linearity for fentanyl and nor-fentanyl in both plasma and saliva was demonstrated from 0.02 to 10 μg/L (R(2) 0.9988-0.9994). Accuracy for fentanyl and nor-fentanyl in both plasma and saliva samples was between 96% and 108%. Total imprecision expressed as the co-efficient of variation was between 1.0 and 15.5% for both analytes in both matrices. The validated method was applied successfully in 11 paired plasma and saliva samples obtained from patients with cancer pain receiving transdermal fentanyl (Duragesic(®)) at doses from 25 μg to 100 μg.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adsorption; Fentanyl; HPLC–MS/MS; Plasma; Saliva; Salivette(®)

Mesh:

Substances:

Year:  2014        PMID: 24780703     DOI: 10.1016/j.jchromb.2014.04.019

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  A Case Study Evaluating the Efficacy of an Ad Hoc Hospital Collection Device for Fentanyl in Infant Oral Fluid.

Authors:  Ashley M Gesseck; Justin L Poklis; Carl E Wolf; Jie Xu; Aamir Bashir; Karen D Hendricks-Muñoz; Michelle R Peace
Journal:  J Anal Toxicol       Date:  2020-10-12       Impact factor: 3.367

2.  Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole.

Authors:  Kim Vanstraelen; Johan Maertens; Patrick Augustijns; Katrien Lagrou; Henriette de Loor; Raf Mols; Pieter Annaert; Anne Malfroot; Isabel Spriet
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

3.  A Novel Oral Fluid Assay (LC-QTOF-MS) for the Detection of Fentanyl and Clandestine Opioids in Oral Fluid After Reported Heroin Overdose.

Authors:  Matthew K Griswold; Peter R Chai; Alex J Krotulski; Melissa Friscia; Brittany P Chapman; Neha Varma; Edward W Boyer; Barry K Logan; Kavita M Babu
Journal:  J Med Toxicol       Date:  2017-10-02

4.  Sub-Part-Per-Billion Level Sensing of Fentanyl Residues from Wastewater Using Portable Surface-Enhanced Raman Scattering Sensing.

Authors:  Boxin Zhang; Xingwei Hou; Cheng Zhen; Alan X Wang
Journal:  Biosensors (Basel)       Date:  2021-10-03

5.  Direct Coupling of Bio-SPME to Liquid Electron Ionization-MS/MS via a Modified Microfluidic Open Interface.

Authors:  Priscilla Rocío-Bautista; Giorgio Famiglini; Veronica Termopoli; Pierangela Palma; Emir Nazdrajić; Janusz Pawliszyn; Achille Cappiello
Journal:  J Am Soc Mass Spectrom       Date:  2020-11-19       Impact factor: 3.109

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.